Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Sponsor: Celgene
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Official title: A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
424
Start Date
2019-09-30
Completion Date
2026-11-30
Last Updated
2024-11-29
Healthy Volunteers
No
Conditions
Interventions
CC-92480
Specified dose on specified days
Bortezomib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Daratumumab
Specified dose on specified days
Carfilzomib
Specified dose on specified days
Elotuzumab
Specified dose on specified days
Isatuximab
Specified dose on specified days
Carfilzomib
Specified dose on specified days
Locations (49)
Local Institution - 119
Denver, Colorado, United States
Local Institution - 104
Tampa, Florida, United States
Local Institution - 108
Atlanta, Georgia, United States
Local Institution - 112
Chicago, Illinois, United States
Local Institution - 107
Chicago, Illinois, United States
Local Institution - 117
Boston, Massachusetts, United States
Local Institution - 101
Boston, Massachusetts, United States
Local Institution - 118
Boston, Massachusetts, United States
Local Institution - 113
Detroit, Michigan, United States
Local Institution - 106
Rochester, Minnesota, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Local Institution - 110
Winston-Salem, North Carolina, United States
Local Institution - 115
Columbus, Ohio, United States
Local Institution - 114
Nashville, Tennessee, United States
Local Institution - 116
Houston, Texas, United States
Swedish Cancer Institute
Seattle, Washington, United States
Local Institution - 201
Calgary, Alberta, Canada
Local Institution - 205
Edmonton, Alberta, Canada
Local Institution - 204
Halifax, Nova Scotia, Canada
Local Institution - 203
Toronto, Ontario, Canada
Local Institution - 202
Montreal, Quebec, Canada
Local Institution - 802
Brno, Czechia
Local Institution - 801
Ostrava-Poruba, Czechia
Local Institution - 803
Prague, Czechia
Local Institution - 902
Odense, Denmark
Local Institution - 903
Vejle, Denmark
Local Institution - 703
Lille, France
Local Institution - 705
Marseille, France
Local Institution - 704
Nantes, France
Local Institution - 701
Toulouse, France
Local Institution - 702
Tours, France
Local Institution - 604
Freiburg im Breisgau, Germany
Local Institution - 605
Hamburg, Germany
Local Institution - 601
Heidelberg, Germany
Local Institution - 602
München, Germany
Local Institution - 603
Würzburg, Germany
Local Institution - 301
Athens, Greece
Local Institution - 404
Brescia, Italy
Local Institution - 401
Milan, Italy
Local Institution - 403
Reggio Emilia, Italy
Local Institution - 402
Torino, Italy
Local Institution - 504
Badalona, Spain
Local Institution - 508
Madrid, Spain
Local Institution - 501
Madrid, Spain
Local Institution - 506
Málaga, Spain
Local Institution - 505
Pamplona, Spain
Local Institution - 502
Salamanca, Spain
Local Institution - 503
Santander, Spain
Local Institution - 507
Valencia, Spain